Last reviewed · How we verify
MCV-AC Vaccine Group
MCV-AC is a meningococcal conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis to prevent meningococcal disease.
MCV-AC is a meningococcal conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis to prevent meningococcal disease. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A and C.
At a glance
| Generic name | MCV-AC Vaccine Group |
|---|---|
| Also known as | Group A and C Meningococcal conjugate vaccine |
| Sponsor | Beijing Minhai Biotechnology Co., Ltd |
| Drug class | Conjugate vaccine |
| Target | Neisseria meningitidis serogroups A and C polysaccharide capsules |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains polysaccharide capsules from meningococcal serogroups A and C conjugated to a carrier protein, which enhances T-cell dependent immune responses and antibody production. This approach improves immunogenicity compared to unconjugated polysaccharide vaccines, particularly in younger populations, and provides protection against invasive meningococcal disease caused by these serogroups.
Approved indications
- Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A and C
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MCV-AC Vaccine Group CI brief — competitive landscape report
- MCV-AC Vaccine Group updates RSS · CI watch RSS
- Beijing Minhai Biotechnology Co., Ltd portfolio CI